Antimicrobial resistance plan published by pharma companies

20 September 2016

A pledge to defeat antimicrobial resistance (AMR) has been signed by many of pharma’s biggest companies during an event hosted as part of the United Nations (UN) General Assembly high-level meeting.

The Roadmap for Progress on Combating Antimicrobial Resistance details 15 specific actions that companies will take forward, including measures to reduce the environmental impact from production of antibiotics, help to ensure that they are only used by patients who need them, improve access to current and future antibiotics, vaccines, and diagnostics, and explore new opportunities for open collaborations between industry and the public sector.

"Today we have underlined our role as key player in the fight against drug resistance"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK